The paper describes some interesting new findings that are likely to inform …

• (Abstract)
• The Dopaminergic Pathway
• Alcohol Withdrawal: the role of glutamate
• Opioid Dependence: what other neurotransmitter systems are involved?
• Ecstacy: the 5-HT system and neurotoxicity
• The Gabaergic System: target for sedatives
• Conclusion
• References

Biology Articles » Neurobiology » Neurobiology of Diseases & Aging » Neurobiology of addiction and implications for treatment » References

References

- Neurobiology of addiction and implications for treatment

Ameri, A. (1999) The effects of cannabinoids on the brain. Progress in Neurobiology, 58, 315-348.

Ascher, J. A., Cole, J. O., Colin, J. N., et al (1995) Bupropion: a review of its mechanism of antidepressant activity. Journal of Clinical Psychiatry, 56, 395-401.

Ashton, C. H. (2001) Pharmacology and effects of cannabis: a brief review. British Journal of Psychiatry, 178, 101-106.

Bisaga, A., Comer, S. D., Ward, A. S., et al (2001) The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology (Berl), 157, 1-10.

Boot, B. P., McGregor, I. S. & Hall, W. (2000) MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet, 355, 1818-1821.

Chiamulera, C., Epping-Jordan, M. P., Zocchi, A., et al (2001) Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nature Neuroscience, 4, 873-874.

Dahchour, A. & De Witte, P. (2000) Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. Progress in Neurobiology, 60, 343-362.

Herz, A. (1997) Endogenous opioid systems and alcohol addiction. Psychopharmacology, 129, 99-111.

Jorenby, D. E., Leischow, S. J., Nides, M. A., et al (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New England Journal of Medicine, 340, 685-691.

Kieffer, B. L. (1999) Opioids: first lessons from knockout mice. Trends in Pharmacological Sciences, 20, 19-26.

Koob, G. F. & Le Moal, M. (2001) Drug addiction, dysregulation of reward, and allostastis. Neuropsychopharmacology, 24, 97-129.

Ledent, C., Valverde, O., Cossu, G., et al (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CBI receptor knockout mice. Science, 283, 401-404.

Louk, J. M. J., Vanderschuren, L. J. & Kalivas, P. W. (2000) Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berl), 151, 99-120.

Maldonado, R., Saiardi, A., Valverde, O., et al (1997) Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature, 388, 586-589.

Manzanares, J., Corchero, J., Romero, J., et al (1999) Pharmacological and biochemical interactions between opioids and cannabinoids. Trends in Pharmacological Sciences, 20, 287-294.

Martin, M., Ledent, C., Parmentier, M., et al (2000) Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CBI knockout mice. European Journal of Neuroscience, 12, 4038-4046.

Nicholson, K. L. & Balster, R. L. (2001) GHB: a new and novel drug of abuse. Drug and Alcohol Dependence, 63, 1-22.

Nutt, D. (1993) Neurochemistry of drugs other than alcohol. Current Opinion in Psychiatry, 6, 395-402.

Nutt, D. (1999) Alcohol and the brain. Pharmacological insights for psychiatrists. British Journal of Psychiatry, 175, 114-119.

Nutt, D. & Malizia, A. L. (2001) New insights into the role of the GABA_A—benzodiazepine receptor in psychiatric disorder. British Journal of Psychiatry, 179, 390-396.

Pilla, M., Perachon, S., Sautel, F., et al (1999) Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature, 400, 371-375.

Reneman, L., Lavalaye, J., Schmand, B., et al (2001) Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings. Archives of General Psychiatry, 58, 901-906.

Rinaldi-Carmona, M., Barth, F., Heaulme, M., et al (1995) Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sciences, 56, 1941-1947.

Risinger, F. O., Freeman, P. A., Rubinstein, M., et al (2000) Lack of operant ethanol self-administration in dopamine D2 receptor knockout mice. Psychopharmacology (Berl), 152, 343-350.

Schultz, W. (2001) Reward signaling by dopamine neurons. Neuroscientist, 7, 293-302.

Semple, D. M., Ebmeier, K. P., Glabus, M. F., et al (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users. British Journal of Psychiatry, 175, 63-69.

Strang, J., Bearn, J. & Gossop, M. (1999) Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. American Journal on Addictions, 8, 337-348.

Volkow, N. D., Fowler, J. S. & Wang, G. J. (1999) Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. Journal of Psychopharmacology, 13, 337-345.

Wolf, M. E. (1998) The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Progress in Neurobiology, 54, 679-720.

Zubieta, J., Greenwald, M. K., Lombardi, U., et al (2000) Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology, 23, 326-334.